Shares of Bayer AG (OTCMKTS:BAYRY) have been assigned an average rating of “Hold” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $17.00.
A number of brokerages have weighed in on BAYRY. Zacks Investment Research lowered Bayer from a “hold” rating to a “sell” rating and set a $17.00 price objective on the stock. in a report on Wednesday, August 7th. ValuEngine lowered Bayer from a “hold” rating to a “sell” rating in a report on Wednesday, September 11th. Finally, Bank of America raised Bayer from a “neutral” rating to a “buy” rating in a report on Friday, August 16th.
BAYRY traded up $0.03 during trading on Friday, reaching $18.13. The company’s stock had a trading volume of 141,820 shares, compared to its average volume of 706,075. Bayer has a 52-week low of $14.61 and a 52-week high of $23.50. The company’s fifty day moving average price is $18.33 and its 200-day moving average price is $17.02. The company has a market capitalization of $67.63 billion, a price-to-earnings ratio of 10.36, a price-to-earnings-growth ratio of 1.00 and a beta of 1.02. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.88 and a current ratio of 1.29.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Article: What is Elliott Wave theory?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.